Ms. Beck brings over 20 years of knowledge and experience from biotechnology and clinical research organizations. She most recently served as vice president, investor relations and administration with Ocugen, Inc., where she played an instrumental role in the growth of the company, including through its reverse merger to become a publicly-traded company on the Nasdaq exchange. Prior to Ocugen, she held roles of increasing responsibility at PRA Health Sciences, DrugDev and Tengion. Ms. Beck holds a B.S. in Business Administration with a concentration in Accounting from Millersville University, a M.S. in Human Resource Development from Villanova University and a M.B.A. with a concentration in Biotechnology and Health Industry Management from Penn State University.
Sandhya Kortagere is the Inventor, Co-founder and Chief Scientific Officer of PolyCore Therapeutics LLC. Dr. Kortagere is a molecular pharmacologist with over 15 years experience in Drug Discovery and Development. She is currently an Associate Professor at Drexel University College of Medicine where she pioneered in the development of a platform technology called the Hybrid Structure Based method to design small molecule modulators to a variety of therapeutically relevant protein targets. Prior to her arrival at Drexel, she was a research and teaching specialist at Robert Wood Johnson Medical school of Rutgers University, NJ. Dr. Kortagere obtained her Ph.D at National Institute of Mental Health and Neurosciences, Bangalore, India in Molecular Pharmacology and pursued her postdoctoral fellowship at Mount Sinai Medical Center and Weill Cornell Medical College at NYC.
Thais Sielecki is the COO at PolyCore Therapeutics LLC. Dr. Sielecki previously worked as Vice President, Preclinical Development of Cytokine PharmaSciences, Inc. At CPSI Dr. Sielecki ran programs from early lead discovery through to Phase I and assisted in Phase II and III study design as her primary focus. As part of the management team, she was also a member of teams to manage product portfolio, in-licensing, intellectual property management, and company strategy. Her experience spans oncology, inflammation, women’s health, CNS diseases, and antibacterials with a strong background in drug delivery and controlled release delivery systems. Dr. Sielecki has a PhD In medicinal chemistry from Colorado State University and completed a Post Doctoral research position at Stanford University. She has over 60 publications and patents over her career.
Dr. Jay Schneider
Professor of Pathology, Anatomy and Cell Biology
Thomas Jefferson University
Dr. Matthew B. Stern
Director Emeritus, Parkinson’s Disease and Movement Disorders Center
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Your Name (required)
Your Email (required)